BLC
SGMO

Brown, Lisle/Cummings’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Brown, Lisle/Cummings’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377 Hold
1,525
– – ﹤0.01% 999
2025
Q4 		$641 Hold
1,525
– – ﹤0.01% 709
2025
Q3 		$1.03K Hold
1,525
– – ﹤0.01% 699
2025
Q2 		$825 Hold
1,525
– – ﹤0.01% 720
2025
Q1 		$1K Hold
1,525
– – ﹤0.01% 710
2024
Q4 		$1.56K Hold
1,525
– – ﹤0.01% 609
2024
Q3 		$1.32K Hold
1,525
– – ﹤0.01% 588
2024
Q2 		$546 Buy
+1,525
New +$824 ﹤0.01% 597

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Brown, Lisle/Cummings's SGMO Position: Q1 2026 in Review

Brown, Lisle/Cummings held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 1,525 shares worth $377. The position accounts for ﹤0.01% of the portfolio, ranked #999.

Brown, Lisle/Cummings first reported a position in SGMO in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.56K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Brown, Lisle/Cummings held 1,525 shares of SANGAMO THERAPEUTICS INC worth $377 as of Q1 2026.
  • Brown, Lisle/Cummings left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #999 holding.
  • Brown, Lisle/Cummings first reported a position in SANGAMO THERAPEUTICS INC in Q2 2024 and has held it in 8 quarters since.
  • Brown, Lisle/Cummings's SANGAMO THERAPEUTICS INC position peaked at $1.56K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.